Full Text
Cost Per Responder Analysis of Guselkumab Versus Etanercept Using Efficacy Results from Pivotal Clinical Trials in Patients with Moderate to Severe Plaque Psoriasis

Abstract

Authors

A Teeple E Muser

Back to Volume 21, Supplemental S1
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×